European Leukemia Trial Registry
Trial: CLDE225X2116

More Details
Title Safety and Efficacy of LDE225 + INC424 in Patients With MF
Scientific Title A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis
Short Title CLDE225X2116
Trialgroup NN
Type of Trial multicentric, single-group, prospective, open-label
Disease Myeloproliferative disease(MPD) Myelofibrosis
Age >= 18 years
Status Active
Start of Recruitment 01.05.2013
Leader Koschmieder, Prof. Dr. med., Steffen
Contactperson

Coordinating Investigator Germany
Koschmieder, Prof. Dr. med., Steffen
Tel: +49 (0)241 8036102
Fax: +49 (0)241 8082449
Email: skoschmieder@ukaachen.de

Shortprotocol Shortprotocol
created 16.10.2013 Johannes Kraus
changed 08.06.2015 Hanna Ebert
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org